Bone Biologics Corporation - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
BBLG Nasdaq 2836 www.bonebiologics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Bone Biologics Corporation

Bone Biologics Expands Trial Sites - Sep 8th, 2026 6:30 am
BBLG Efficiency Improves as Crucial Trials Advance - Aug 17th, 2026 6:46 am
Bone Biologics Extends rhNELL-1 Validated Shelf Life to 32 Months as NB1 Study Advances - Aug 12th, 2026 8:15 am
Bone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1 - Aug 12th, 2026 6:00 am
Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities - Jul 23rd, 2026 6:00 am
BBLG Secures Financing for Critical Trials - Jul 8th, 2026 6:15 am
Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules - Jul 7th, 2026 6:00 pm
Bone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1 - May 19th, 2026 6:00 am
BBLG In Good Shape as Critical Tests Underway - May 15th, 2026 6:29 am
BBLG Approaching Crucial Stage - Feb 25th, 2026 4:06 am
Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook - Jan 8th, 2026 6:00 am
Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months - Dec 23rd, 2025 6:00 am
BBLG Has Cash for Approval Push - Nov 17th, 2025 5:08 am